Gilead Gets Option To Tizona's Novel HLA-G Checkpoint, Further Bulking Up Immune Checkpoint Arsenal

 
• By Jessica Merrill

The big biotech will pay $300m to acquire a 49.9% equity interest in the cancer immunotherapy startup with a buyout option. It is one of several immune checkpoints Gilead has secured access to this year.

Photo of handshake of business partners after striking deal
Gilead strikes a deal with Tizona • Source: Shutterstock

More from Deals

More from Business